Literature DB >> 18182078

Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.

Esa Jantunen1, Taru Kuittinen.   

Abstract

More than 15,000 autologous stem cell transplants (ASCT) were reported to European Blood and Bone Marrow Transplantation registry in 2005, most commonly for multiple myeloma (MM) and lymphomas. In 98% of the cases high-dose therapy was supported by blood stem cells. Thus stem cell mobilization and collection are integral parts of ASCT protocols. We give here a practical approach to blood stem cell mobilization and collection in patients with various lymphoproliferative diseases. While mobilization is usually easy and straightforward in patients with MM, about 10-20% of patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma are hard-to-mobilize. There seems to be even more disease-specific issues in blood stem cell mobilization in patients with chronic lymphocytic leukaemia and in patients with light chain amyloidosis. We also discuss options in hard-to-mobilize patients.

Entities:  

Mesh:

Year:  2007        PMID: 18182078     DOI: 10.1111/j.1600-0609.2007.01026.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT.

Authors:  Allison L Bayer; Monica Jones; Jackeline Chirinos; Lesley de Armas; Taylor H Schreiber; Thomas R Malek; Robert B Levy
Journal:  Blood       Date:  2008-10-02       Impact factor: 22.113

2.  Mobilized hematopoietic stem cell yield depends on species-specific circadian timing.

Authors:  Daniel Lucas; Michela Battista; Patricia A Shi; Luis Isola; Paul S Frenette
Journal:  Cell Stem Cell       Date:  2008-10-09       Impact factor: 24.633

3.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.